Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2021
Pharma News, 2021
GeneTx and Ultragenyx Announce FDA has Removed Clinical Hold on Phase 1/2 Clinical Study of GTX-102 for the Treatment of Angelman Syndrome in the U.S.
SARASOTA, Fla.
ReveraGen and Santhera Announce FDA Orphan Grant Funding for Clinical Trial with Vamorolone in Becker Muscular Dystrophy
Rockville, MD, USA, and Pratteln, Switzerland, September 27, 2021 – ReveraGen Biopharma and Santhera Pharmaceuticals (SIX.
Japan panel approves second drug for mildly ill COVID-19 patients
A health ministry expert committee on Monday approved a single-dose monoclonal antibody-based treatment developed by British drugmaker GlaxoSmithKline PLC and U.
Pfizer begins study of oral drug for prevention of COVID-19
Sept 27 (Reuters) - Pfizer Inc (PFE.
The FDA accelerated drug approval program: benefits and limitations
The aim of the US Food and Drug Administration’s Accelerated Approval Program (AAP) is to expedite the development of new therapies that address an unmet need in the treatment of serious dis...
FDA approves ready-to-use norepinephrine injections for severe hypertension
Baxter International has received FDA approval for its premixed doses of Norepinephrine Bitartrate in 5% Dextrose Injection, a ready-to-use treatment for patients with severe, acute hypertension.
Alrizomadlin Lands FDA Fast Track Designation for Melanoma
Alrizomadlin, a MDM2-p53 inhibitor has been granted a fast track designation by the FDA for the treatment of relapsed/refractory unresectable or metastatic melanoma who are relapsed or refractory to p...
AstraZeneca to discover and develop self-amplifying RNA therapeutics in new collaboration with VaxEquity
AstraZeneca has reached an agreement to collaborate with VaxEquity for the discovery, development and commercialisastion of the proprietary self-amplifying RNA (saRNA) therapeutics platform de...
CARISMA Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to CT-0508 for the Treatment of Patients with Solid Tumors
PHILADELPHIA, Sept.
SAGE-718 on FDA Fast Track as Potential Huntington’s Therapy
The U.
FDA Approves Opzelura as Treatment for Atopic Dermatitis
In clinical trials, the majority of patients with atopic dermatitis treated with ruxolitinib had clear or almost clear skin.
Micro-robots propelled by air bubbles and ultrasound
Some engineers find inspiration in the mechanics of bird flight and the architecture of bee nests.
13
14
15
16
17
18
19
20
21
